Kroger pharmacies add Zepbound KwikPen
“Our customers and communities want affordable, effective weight-management treatment options with real affordability,” said Colleen Lindholz, group vice president and president of Kroger Health.
“Our customers and communities want affordable, effective weight-management treatment options with real affordability,” said Colleen Lindholz, group vice president and president of Kroger Health.
The success of Eli Lilly’s Zepbound is encouraging efforts to expand access to obesity treatments by clarifying pricing and reducing costs.
Used by millions of patients worldwide, the KwikPen for single-patient use offers a new option for receiving Zepbound.
The $3.5 billion Lehigh Valley site will develop Lilly's next-generation weight-loss medicines, including retatrutide.
Strive Compounding Pharmacy accuses drugmakers of anti-competitive actions to suppress lawful compounded GLP-1 medications and restrict patient choice.
The drugmaker’s GLP-1 portfolio achieved triple-digit sales growth in Q3, strengthening Lilly’s leadership in the growing weight-loss market.
Prices for Wegovy, Ozempic, and Zepbound drop from over $1,000 to $350 with the new deal. Medicare coverage begins for GLP-1 obesity drugs for the first time.
The enhanced facility will be among those that will manufacture for orforglipron, Lilly’s first oral, small-molecule GLP-1 receptor agonist.
Eli Lilly announced its Team USA lineup for the 2026 Winter Games. The company will also expand its Milestones into Meaning program.
“Moderate-to-severe obstructive sleep apnea is more than just snoring – it’s a serious condition and it deserves serious attention,” O’Neal said.
The acquisition strengthens Lilly’s genetic medicine pipeline and expands its footprint in ophthalmology.
Lilly’s oral GLP-1 pill helped patients lose 22 pounds and lower A1C in a Phase 3 trial, with global filings planned this year.
Will include a planned investment up to a $250 million to accelerate pharmaceutical innovation.
Eli Lilly and Company enhances digital healthcare offerings to address delays in diagnosis and treatment.